https://scilexholding.gcs-web.com/node/10826/html

ChatGPT- AI generated analysis. May have errors. Do your own due diligence. Not financial advice.

This article was posted in r/dvlt

This is another example of how Datavault AI is trying to position itself beyond being viewed as just a small-cap speculative AI company and instead as an infrastructure/platform company tied to:
AI-driven enterprise data monetization
tokenization of real-world assets (RWA)
blockchain-based rights management
digital asset infrastructure
regulated financial innovation ecosystems
A few things stand out strategically from this announcement:
Why the Zurich / Switzerland angle matters
Switzerland — especially Zurich — has become one of the more crypto- and tokenization-friendly financial jurisdictions globally.
AssetRush appears focused on:
tokenization
alternative assets
fintech infrastructure
digital securities
institutional innovation
So DVLT becoming the “main strategic partner” is more about:
credibility signaling
institutional networking
European visibility
attracting enterprise partnerships
than immediate revenue.
This aligns with their recent messaging around:
CLARITY Act positioning
distributed edge GPU infrastructure
NYIAX acquisition
tokenized data/IP ecosystems
AI governance discussions
RWA/tokenization narratives
Why this could matter for DVLT
If DVLT succeeds, the larger vision appears to be:
Convert enterprise data/IP into measurable assets
Score/value those assets
Potentially tokenize or structure them
Enable monetization/licensing/trading ecosystems around them
That is a very ambitious thesis because it touches:
finance
AI
blockchain
compliance
intellectual property law
enterprise SaaS
cloud infrastructure
The IBM relationship mentioned again is important because DVLT repeatedly uses IBM affiliation as enterprise-validation messaging.
Important investor reality check
The article is mostly:
branding
positioning
ecosystem signaling
conference prestige
It is not:
a revenue announcement
a major customer contract
regulatory approval
proof of adoption at scale
For speculative companies like DVLT, investors usually need to separate:
narrative expansion
vs.
measurable commercial execution
Key future things that would matter more materially:
recurring enterprise revenue
large signed contracts
successful NYIAX integration
actual tokenized asset transactions
GPU deployment execution
cash flow improvement
reduced dilution risk
Bigger pattern you may be noticing
DVLT is increasingly trying to insert itself into multiple emerging narratives simultaneously:
AI infrastructure
RWA tokenization
digital rights/IP monetization
sports/media licensing
healthcare/pharmacy AI
blockchain-enabled exchanges
cybersecurity/governance
edge compute
That creates:
potentially very large TAM narratives
but also
execution complexity
financing needs
credibility challenges
This Zurich partnership supports the idea that DVLT wants international institutional relevance in tokenized finance, not just retail-investor attention.

On round 1 I submitted two different opt in forms--one for each brokerage firm. When I try to do that this time it's kicking it back saying I can only use one opt in form. Do I just put both brokerages on the same form with their corresponding information?

https://x.com/datavault_ai/status/2057188889048092721?s=46&t=oThPor35yxODq7z_-6n5eg

https://m.youtube.com/watch?v=nxNfQZLXocw

https://x.com/commercegov/status/2056835747391361323?s=46&t=oThPor35yxODq7z\_-6n5eg

https://x.com/kshaughnessy2/status/2056769426255471069?s=46&t=oThPor35yxODq7z\_-6n5eg

ChatGPT- AI generated analysis. May have errors. Do your own due diligence. Not financial advice.

Key takeaways from this Wellgistics Health, Inc. update:
Why this matters for
Datavault AI Inc.
The biggest market-moving item is that WGRX said it is in “advanced discussions” with DVLT regarding a binding term sheet to expand the PharmacyChain™ license into broader Health-as-a-Service (HaaS) capabilities.
That is materially stronger language than a casual partnership mention because:
They specifically referenced a binding term sheet
They tied it to:
blockchain-enabled pharmacy infrastructure
HIPAA-compliant data transfer
AI dispensing workflows
smart-contract prescription processing
telepharmacy scaling
This suggests DVLT is trying to position PharmacyChain™ as a real healthcare data/tokenization infrastructure layer rather than only a concept/demo product.

Most important business signals
1. WGRX revenue growth is accelerating
Revenue trend:
Q4 2025: ~$486K
Q1 2026: ~$929K
Q2 2026 projected: ~$1.775M
That is meaningful sequential growth for a microcap healthcare platform. They are trying to show:
actual pharmacy dispensing activity
direct-to-patient revenue
recurring operational scale
The market will still question profitability and dilution risk, but at least there is evidence of commercial traction rather than only PR.

2. DVLT’s PharmacyChain™ is moving deeper into healthcare infrastructure
The press release repeatedly links:
EinsteinRx™ AI pharmacy hub
PharmacyChain™ blockchain infrastructure
HIPAA-compliant data transfer
smart contracts
telehealth
adherence monitoring
AI coaching
This is important because it reframes DVLT from:
“AI/tokenization story stock”
toward:
“regulated healthcare workflow infrastructure”
That could potentially attract:
healthcare distributors
PBMs
specialty pharmacy operators
GLP-1 ecosystem participants
compliance-focused enterprise partners
if execution is real.

3. GLP-1 strategy appears central
WGRX clearly emphasized:
GLP-1 market expansion
weight-loss support ecosystem
Forzet™ medical food
compliance/adherence tools
This aligns with one of the hottest healthcare spending areas right now.
They appear to be trying to build:
prescription fulfillment
telehealth
coaching
nutrition support
monitoring
recurring subscription engagement
around GLP-1 patients.
That creates potentially high recurring revenue per patient if adoption occurs.

4. Kare Pharmtech JV may be more important than the market realizes
The JV supposedly gives access to:
telepharmacy infrastructure
operational pharmacy scaling
200,000+ patient lives
If legitimate and successfully onboarded, this becomes the operational backbone needed to justify:
AI automation
blockchain tracking
smart contracts
prescription routing
Without dispensing volume, PharmacyChain™ would remain mostly theoretical.

Bull case
For WGRX
Rapid revenue growth
Cost cutting improved losses substantially
Direct-to-consumer healthcare model
Exposure to GLP-1 wave
NFL Alumni Health branding could improve visibility
Potential differentiated pharmacy-tech ecosystem
For DVLT
Another real-world deployment narrative
Healthcare is a much larger TAM than NFT/media tokenization
HIPAA + pharma distribution use cases sound more institutionally credible
Could validate PharmacyChain™ commercially

Bear case / risks
Important risks investors should not ignore:
1. Still extremely early-stage
Revenue remains small:
<$2M quarterly run-rate projected
while losses are still substantial.

2. Many initiatives are still aspirational
The release heavily uses phrases like:
“targeted”
“anticipated”
“expected”
“pending”
“advanced discussions”
Meaning:
much is not finalized yet
execution risk remains enormous

3. Blockchain healthcare adoption is difficult
Healthcare systems move slowly because of:
HIPAA
integration complexity
pharmacy regulations
PBM structures
insurer interoperability issues
Commercial adoption could take years.

4. Microcap financing risk
Both WGRX and DVLT remain speculative small-cap companies.
Potential concerns:
dilution
convertible financing
Nasdaq compliance pressure
execution financing needs

Interesting strategic angle
This release hints DVLT may be evolving toward:
regulated enterprise infrastructure
healthcare tokenization
secure data monetization
compliance-grade AI ecosystems
rather than only media/licensing/token hype.
That is probably the most important long-term implication here.
If they successfully demonstrate:
secure prescription data routing
pharmacy smart contracts
HIPAA-compliant tokenized workflows
then larger healthcare/pharma players may eventually pay attention.
But investors will likely want to see:
signed definitive agreements
actual customer deployments
measurable transaction volume
audited recurring revenue
proof the blockchain layer is genuinely necessary
before assigning major valuation premiums.

DVLT every day minus 10 precent right after the opening bell - reminds me of SRNE.

Obviously somebody wants to destroy it.

https://semnurpharma.gcs-web.com/node/6656/html

Okay Henry. It’s that time! Put up or shut up. Since September of last year, there have been many moves made since your official return as CEO of pretty much everything. I was going to list many of them but most of our BoB community know them well. All these moves have apparently been done to bring SHAREHOLDER VALUE to us. Well, this hasn’t quite worked out to date. It’s been 9 months since then and we have nothing to show for our patience but some currently worthless meme coins. I have been trying to remain positive since these moves began but given your history, it’s hard not to think some of these moves at least rhyme with past moves.

Our goals are aligned. We ALL want you to be successful along with recovering some or all of our investment in YOU primarily. We know what you’ve been through but remember WE’VE BEEN THROUGH IT TOO! I’ve said this countless times but I will repeat myself. The only way we get these shorts off our backs is to SELL SOMETHING (aka SEMDEXA or SEMNUR as a whole) for big $. Short of this will result in more of the same. The fact that we didn’t receive our Semnur divvies led me to believe something was in the works. But it’s been months now so I’m starting to remember the old tricks you used. Meme coins every month to keep us holding on, all the while you engaging in these financial engineering tricks finding creative ways to potentially enrich yourself. Well, it’s time to share Henry. I have a bearish theory that isn’t my base case but if I put my neutral hat on, the moves could be taken in a positive light wearing a bullish hat and also a negative light wearing a bearish hat. Only you know because you haven’t spoken a word to us!

This upcoming AGM on June 24th will tell us all what you are really up to. These incentives that are up for a vote should absolutely NOT be included. The nerve of asking for MORE after you gifted yourself a ton of warrants and had your options repriced, and got Scilex to pay for your Vivasor assets, it’s all starting to look a bit too familiar.

THE TIME HAS ARRIVED!! Think about someone other than yourself. We’ve suffered long enough waiting for you to get something to market. You can get paid handsomely IF we get paid for our loyalty.

************SHOW ME THE MONEY!************

ChatGPT- AI generated analysis. May have errors. Do your own due diligence. Not financial advice.

The article is referring to a potentially major shift by the U.S. Securities and Exchange Commission toward allowing blockchain-based trading of tokenized stocks and securities under a temporary “innovation exemption” framework.
Key points:
The SEC is reportedly preparing an “innovation exemption” that could allow crypto-native platforms to trade tokenized versions of stocks without immediately complying with the full traditional exchange/broker-dealer framework.
This exemption is expected to be limited in scope and time, more like a regulatory sandbox while the SEC develops permanent rules.
SEC Chair Paul Atkins and Commissioner Hester Peirce have both publicly discussed the idea in speeches and crypto conferences.
What “tokenized securities” means:
A traditional stock (like Apple or Tesla) is represented digitally on a blockchain as a token.
Benefits supporters claim:
24/7 trading
faster settlement
fractional ownership
easier collateralization
integration with DeFi and crypto wallets
Important nuance:
The SEC has repeatedly emphasized that “tokenized securities are still securities.” Existing investor-protection laws still apply.
Some tokenized shares may NOT provide normal shareholder rights like voting or dividends depending on structure.
There is controversy over whether third parties could issue tokenized versions of stocks without the company’s permission.
Why this matters for companies like:
Datavault AI Inc.
Scilex Holding Company
crypto/RWA ecosystems
This potentially validates broader:
tokenization infrastructure
blockchain settlement systems
digital identity/compliance systems
AI + data monetization ecosystems
DeFi-linked capital markets
That is why many small-cap AI/blockchain companies are discussing:
RWAs (real-world assets)
tokenized equities
decentralized exchanges
compliance layers
custody infrastructure
edge compute/data validation
The SEC initiative also connects with the Senate’s broader crypto legislation efforts like the CLARITY Act discussions.
The biggest unresolved questions:
Will crypto platforms get lighter regulation than NYSE/Nasdaq?
Will tokenized shares have full shareholder rights?
How will custody and fraud risks be handled?
Can decentralized exchanges legally trade securities?
Will this fragment liquidity away from traditional markets?
Traditional exchanges and industry groups have strongly pushed back, warning about:
regulatory arbitrage
weaker investor protections
market fragmentation
The overall significance:
This could become one of the biggest structural changes to U.S. capital markets since electronic trading, if the SEC formally opens a compliant pathway for on-chain securities trading.

https://x.com/adportsgroup/status/2056345315306017173?s=46&t=oThPor35yxODq7z\_-6n5eg

"The summer soldier and the sunshine patriot will, in this crisis, shrink from the service of their country; but he that stands by it now, deserves the love and thanks of man and woman. Tyranny, like hell, is not easily conquered; yet we have this consolation with us, that the harder the conflict, the more glorious the triumph."

~ Thomas Paine, The American Crisis

It's just another MONDAY, Gang. We'll get there !!! 🙏🤞🙏

💥💥💥 OUR WORLD 💥💥💥

This is CHatGPT - AI generated analysis. There can be errors. Not financial advise. Do your Own Due Diligence.

Just wanted share what we have invested into. Any and all corrections are welcome.

Vivasor info added in response to Incamp2001. Thank you for pointing out.

Dr. Henry Ji “Universe” — Global Ecosystem Chart (May 2026)

Entity	Primary Focus	Key Products / Technologies	Development Stage	Subsidiaries / Controlled Entities	Major Partnerships	Foreign Country Connections / International Presence
Scilex Holding Company	Non-opioid pain therapeutics	ZTlido®, ELYXYB®, Gloperba®, SEMDEXA™, SP-103, SP-104	Commercial + late-stage pipeline	SCLX Stock Acquisition JV LLC; controlling interest in Semnur Pharmaceuticals	Oramed Pharmaceuticals, Datavault AI Inc., St. James Bank & Trust	Canada regulatory activity (ELYXYB); Bahamas financing structure via St. James Bank; international investor base
Semnur Pharmaceuticals	Sciatica & pain therapeutics	SEMDEXA™ (SP-102)	Phase 3 completed	Controlled by Scilex	Linked financing and governance overlap with Scilex	U.S.-focused currently, but potential global commercialization path if approved
Sorrento Therapeutics	Broad biotech platform	Oncology, antivirals, pain, diagnostics, cell therapy	Restructuring / asset monetization	Historical ownership stakes in Scilex, Virex and multiple development entities	Lee's Pharmaceutical Holdings, Mayo Clinic collaborations, DARPA-related programs	Major historical China/Hong Kong partnerships through Lee’s Pharma; global antibody and oncology licensing ambitions
ACEA Therapeutics	Oncology therapeutics	Small-molecule oncology programs	Clinical stage	ACEA Pharma subsidiary	Pending acquisition by Phoenix Asia Holdings Limited	Strong China links historically through ACEA biosciences/origin relationships
Phoenix Asia Holdings Limited	Acquisition/holding structure	ACEA Pharma acquisition vehicle	Transaction stage	Expected ownership of ACEA Pharma	ACEA transaction; capital markets relationships	Asia-focused corporate structure and investor positioning
Datavault AI Inc.	AI, tokenization, edge infrastructure	ADIO®, DVHolo, tokenization systems, distributed GPU edge network	Commercial expansion	Distributed infrastructure initiatives	IBM, NYIAX acquisition agreement, Scilex investment relationship	Korea/Samsung meeting activity; global tokenization positioning; international data-center ambitions across multiple regions
Virex Health	Biosensor diagnostics	Rapid testing platforms	Development stage	Historically tied to Sorrento ecosystem	Academic/research collaborations	Potential international diagnostic deployment pathways
Celularity Inc.	Placental-derived cell therapy	Oncology & regenerative medicine programs	Clinical stage	Independent	Historic overlap with Ji/Sorrento investor ecosystem	International cell-therapy market potential
ImmunityBio	Immunotherapy & oncology	ANKTIVA®	Commercial + clinical expansion	Independent	U.S. oncology networks	International oncology expansion ambitions
Oramed Pharmaceuticals	Oral drug delivery	Oral insulin platform	Clinical stage	Independent	Scilex financing/warrant relationship	Israel-based biotech with global licensing reach
Lee's Pharmaceutical Holdings	China/HK pharmaceutical commercialization	Oncology & biologics commercialization	Commercial	China/HK operations	Historical Sorrento licensing partner	Hong Kong and mainland China commercialization infrastructure

Product & Pipeline Matrix

Product / Technology	Company	Therapeutic / Commercial Area	Status	Geographic Notes
ZTlido®	Scilex Holding Company	Post-herpetic neuralgia pain patch	FDA Approved / Commercial	U.S. commercialization
ELYXYB®	Scilex Holding Company	Migraine oral solution	FDA Approved	Canada expansion efforts
Gloperba®	Scilex Holding Company	Gout flare prophylaxis	FDA Approved	U.S. market
SEMDEXA™	Semnur Pharmaceuticals	Sciatica epidural injection	Phase 3 completed	Potential global pain market opportunity
SP-103	Scilex Holding Company	Acute pain topical lidocaine	Phase 2	U.S.-centric currently
SP-104	Scilex Holding Company	Fibromyalgia	Phase 1	Early-stage
ADIO®	Datavault AI Inc.	Audio watermarking/authentication	Commercialization stage	Sports, entertainment, NIL, global media applications
DVHolo	Datavault AI Inc.	Holographic likeness/IP monetization	Early commercialization	International media and sports potential

International Connections & Structures

Country / Region	Connected Entities	Nature of Relationship
China	Sorrento Therapeutics, ACEA Therapeutics, Lee's Pharmaceutical Holdings	Licensing, oncology development, historical biotech collaborations
Hong Kong	Lee's Pharmaceutical Holdings	Commercialization and licensing platform
Bahamas	Scilex Holding Company	Financing/collateral lending through St. James Bank & Trust
Israel	Oramed Pharmaceuticals	Financing and biotech collaboration relationship
Canada	Scilex Holding Company	ELYXYB commercialization/regulatory expansion
South Korea	Datavault AI Inc.	AI/data-center/tokenization meetings and strategic outreach
United Kingdom	Investor and financing exposure across ecosystem	Capital markets and biotech investor presence
Asia-Pacific	Phoenix Asia Holdings Limited, Datavault AI Inc.	Acquisition structures and tokenization/AI market positioning

Simplified “Universe” Relationship Flow

Core Entity	Connected To	Connection Type
Sorrento Therapeutics	Scilex Holding Company	Former parent/spinout
Scilex Holding Company	Semnur Pharmaceuticals	Controlled subsidiary
Scilex Holding Company	Datavault AI Inc.	Strategic investment/collateral relationship
ACEA Therapeutics	Phoenix Asia Holdings Limited	Pending acquisition
Sorrento Therapeutics	Lee's Pharmaceutical Holdings	China/HK licensing partnership
Datavault AI Inc.	IBM	AI infrastructure partnership ecosystem

Major Strategic Themes

Theme	Explanation
Non-opioid pain dominance	Scilex/Semnur remain the centerpiece through commercial pain products and SEMDEXA
Global biotech ties	Historical China/Hong Kong relationships via ACEA and Lee’s Pharma remain important
AI + tokenization expansion	DVLT adds a technology/infrastructure branch extending beyond biotech
Financing complexity	Bahamas loans, warrants, SPACs, and collateral structures interconnect multiple entities
Spinout ecosystem	Many entities originated from or were connected to Sorrento’s historical pipeline strategy
Retail investor focus	Heavy attention on spin-offs, dividends, short-interest dynamics, and hidden asset valuation

https://x.com/palikaras/status/2055777994778530067?s=46&t=oThPor35yxODq7z\_-6n5eg

https://x.com/unusual_whales/status/2056201020125130996?s=46&t=oThPor35yxODq7z_-6n5eg

https://x.com/unusual\_whales/status/2056163103818100998?s=46&t=oThPor35yxODq7z\_-6n5eg